Marginal zone lymphoma: 2023 update on diagnosis and management
American Journal of Hematology · 2023-10 · 98 (10) · 1645-1657
DOI: 10.1002/ajh.27058 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 21.08.2023. Verfasst von Chan Y Cheah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Marginal Zone. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Disease overview Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma. Diagnosis Three subtypes of MZL are recognized: splenic, extranodal, and nodal. The diagnosis is secured following biopsy of an involved nodal or extranodal site demonstrating a clonal B‐cell infiltrate with CD5 and CD10 negative immunophenotype most common. Some cases will features IgM paraprotein, but MYD88 L256P mutations are less frequent than in Waldenstrom macroglobulinemia. Prognostication Several prognostic models have been developed, including the MALT‐IPI and the MZL‐IPI. The latter is broadly applicable across MZL subtypes and incorporates elevated serum LDH, anemia, lymphopenia, thrombocytopenia and nodal or disseminated subtypes as independent predictors of outcome. Treatment We discuss suggested approach to therapy for both early and advanced‐stage disease, with reference to chemo‐immunotherapy, radiotherapy, and emerging treatments in relapsed/refractory disease such as BTK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.
- Medical School, University of Western Australia, Crawley, Australia.
- Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
ORCID-Profile: Chan Y Cheah
Zitieren
APA
Cheah, C. Y., & Seymour, J. F. (2023). Marginal zone lymphoma: 2023 update on diagnosis and management. American Journal of Hematology, 98(10), 1645-1657. https://doi.org/10.1002/ajh.27058
Vancouver
Cheah CY, Seymour JF. Marginal zone lymphoma: 2023 update on diagnosis and management. American Journal of Hematology. 2023;98(10):1645-1657. doi:10.1002/ajh.27058
BibTeX
@article{Cheah2023,
author = {Cheah, Chan Y and Seymour, John F},
title = {Marginal zone lymphoma: 2023 update on diagnosis and management},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {10},
pages = {1645--1657},
doi = {10.1002/ajh.27058}
}
EUVIMED